In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1812-1814

  Barchiesi, Francesco ^a   Di Francesco, Luigi Falconi ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE;

ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DILUTION; DRUG POTENTIATION; DRUG SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0030856523     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1812     Document Type: Article

References (20)

1. Anaissie, E., V. Paetznick, and G. P. Bodey. 1991. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob. Agents Chemother. 35:1641-1646.
2. Balfour, J. A., and D. Faulds. 1992. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 43:259-289.
3. Barchiesi, F., A. L. Colombo, D. A. McGough, and M. G. Rinaldi. 1994. Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. J. Clin. Microbiol. 32:2494-2500.
4. Barchiesi, F., M. Del Poeta, V. Morbiducci, F. Ancarani, and G. Scalise. 1993. Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. Mycopathologia 124:19-25.
5. Barchiesi, F., R. J. Hollis, D. A. McGough, G. Scalise, M. G. Rinaldi, and M. G. Pfaller. 1995. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin. Infect. Dis. 20:634-640.
6. Barchiesi, F., L. K. Najvar, M. F. Luther, G. Scalise, M. G. Rinaldi, and J. R. Graybill. 1996. Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model. Antimicrob. Agents Chemother. 40:1317-1320.
7. Boken, D. J., S. Swindells, and M. G. Rinaldi. 1993. Fluconazole-resistant Candida albicans. Clin. Infect. Dis. 17:1018-1021.
8. Fothergill, A. W., I. Leitner, J. G. Meingassner, N. S. Ryder, and M. G. Rinaldi. 1996. Combination antifungal susceptibility testing of terbinatine and the triazoles fluconazole and itraconazole, abstr. E53, p. 91. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Koneman, E. W., S. D. Allen, W. M. Janda, P. C. Schreckenberger, and W. C. Winn, Jr. 1992. Antimicrobial susceptibility testing, p. 609-668. In E. W. Koneman, S. D. Allen, W. M. Janda, P. C. Schreckenberger, and W. C. Winn, Jr. (ed.), Diagnostic microbiology, 4th ed. J. B. Lippincott Company, Philadelphia, Pa.
10. Kovarik, J. M., E. A. Mueller, H. Zehender, J. Denouël, H. Caplan, and L. Millerioux. 1995. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob. Agents Chemother. 39:2738-2741.
11. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing for yeasts. Tentative standard. Document M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Nguyen, M. G., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
13. Petranyi, G., J. G. Meigassner, and H. Mieth. 1987. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob. Agents Chemother. 31:1365-1368.
14. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, and M. G. Rinaldi. 1994. Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. J. Clin. Microbiol. 32:1650-1653.
15. Pfaller, M. A., S. A. Messer, and S. Coffmann. 1995. Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test live antifungal agents, including the new triazole D0870. J. Clin. Microbiol. 33:1094-1097.
16. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
17. Rex, H. J., M. A. Pfaller, M. Lancaster, F. C. Odds, A. Bolmstron, and M. G. Rinaldi. 1996. Quality control guidelines for National Committee for Clinical Laboratory Standards-recommended broth macrodilution testing of ketoconazole and itraconazole. J. Clin. Microbiol. 34:816-817.
18. Sanguineti, A., J. K. Carmichael, and K. Campbell. 1993. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch. Intern. Med. 153:1122-1124.
19. Warren, N. G., and H. J. Shadomy. 1991. Yeasts of medical importance, p. 617-629. In A. Balows, W. J. Hausler, Jr., K. L. Herrmann, H. D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
20. Yu, V. L., J. J. Zuravleff, J. Bornholm, and G. Archer. 1984. In-vitro synergy testing of triple antibiotic combination against Staphylococcus epidermidis isolates from patients with endocarditis. J. Antimicrob. Chemother. 14:359-366.